SAN DIEGO, Oct. 29, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...
Viking Therapeutics, Inc. (VKTX) is gearing up to initiate a phase 3 study using its subcutaneous formulation of its candidate VK2735 for the treatment of patients with obesity. It is expected to ...
Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens to be Evaluated SAN DIEGO, Oct. 21, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results